AKRX News 35.14 07/16/2014 04:28:05 Akorn Inc (AKRX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Akorn Inc (AKRX) 35.14 $AKRX

Akorn, Inc. Announces Second Quarter 2014 Earnings Release and Conference Call Information
GlobeNewswire - 35 mins ago
Akorn, Inc. (Nasdaq:AKRX) will host a conference call on Tuesday, August 5, 2014, to discuss second quarter 2014 results followed by a Q&A session. The company will release earnings the same day before the market opens.

Progenics Pharmaceuticals, Inc. (PGNX) in Focus: Stock Rises 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 7:44AM CDT
Progenics Pharmaceuticals, Inc. (PGNX) was a big mover last session, as the company saw its shares rise over 8% on the day.

Stocks Recover Impressively; Gap Slumps In After Hours
at Investor's Business Daily - Thu Jul 10, 4:22PM CDT
Major averages ended with modest losses Thursday, recovering impressively after an early sell-off. Wall Street was rattled early over newfound concerns about the health of European banks after Espirito Santo International, the parent company of...

Supernus Up on Non-Dilutive Royalty Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 3:43PM CDT
Supernus Pharmaceuticals, Inc.'s (SUPN) inked a non-dilutive royalty deal worth $30 million with HealthCare Royalty Partners.

Stocks Claw Way Back After Morning Sell-Off
at Investor's Business Daily - Thu Jul 10, 12:42PM CDT
Stocks continued to claw their way back from opening losses Thursday, with the indexes coming more than halfway back in early-afternoon trading. The Nasdaq and S&P 500 fell less than 0.4% and the Dow Jones industrial average was off 0.5%. Volume was...

Shares of AKRX Up 32.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jul 10, 9:41AM CDT
SmarTrend identified an Uptrend for Akorn (NASDAQ:AKRX) on April 22nd, 2014 at $24.55. In approximately 3 months, Akorn has returned 32.59% as of today's recent price of $32.55.

Acasti Pharma Inc. (ACST) Jumps: Stock Rises 7.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 8:21AM CDT
Acasti Pharma Inc. (ACST) was a big mover last session, as the company saw its shares rise by roughly 8% on the day.

Walgreens Sees Robust Growth in June Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 5:20PM CDT
Walgreens (WAG) opened 39 new drug stores in the third-quarter of fiscal 2014 in an attempt to optimize its store footprint.

Teva's Contraceptive Gets Positive CHMP Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 5:00PM CDT
Teva Pharmaceutical Industries Ltd.'s (TEVA) extended-regimen oral contraceptive, Seasonique got a positive recommendation from theCommittee for Medicinal Products for Human Use.

Stocks Add To Losses; TAL Education Bucks Weakness
at Investor's Business Daily - Mon Jul 07, 12:41PM CDT
Stocks worsened a little more Monday afternoon, with techs taking the hardest hit. The Nasdaq stretched its loss to 0.7%. Solar, software and biotechs were among the day's worst-performing groups. The S&P 500 and the Dow Jones industrial average lost...

Salix, Jazz Lead As Drugmakers Pace IBD 50 For Week
at Investor's Business Daily - Thu Jul 03, 5:26PM CDT
It was a healthy week for leaders, with more than 20% of the IBD 50 list of top-rated growth stocks pressing to new highs. Three of those staged breakouts, and nearly two-in-five on the list continued intently working on base patterns. Drugmakers...

Akorn Shares Up 40.0% Since SmarTrend's Buy Recommendation (AKRX)
Comtex SmarTrend(R) - Thu Jul 03, 9:13AM CDT
SmarTrend identified an Uptrend for Akorn (NASDAQ:AKRX) on April 22nd, 2014 at $24.55. In approximately 2 months, Akorn has returned 39.98% as of today's recent price of $34.37.

Edwards Lifesciences Monitor Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 2:00PM CDT
Edwards Lifesciences' (EW) ClearSight system is the most advanced non-invasive hemodynamic monitor that amplifies a physician's access to a patient's advanced hemodynamic parameters.

Early Briefing on Pharma Stocks -- Research on Novartis, Akorn, Horizon Pharma, and Mallinckrodt
PR Newswire - Wed Jul 02, 5:50AM CDT
On Tuesday, July 1, 2014, the NASDAQ Composite ended at 4,458.65, up 1.14%, the Dow Jones Industrial Average advanced 0.77%, to finish the day at 16,956.07, and the S&P 500 closed at 1,973.32, up 0.67%. The gains were broad based with nine out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index ended the day at 713.38, up 1.26%, with the index advancing 4.64% in the previous three months. Investor-Edge has initiated coverage on the following equities: Novartis AG (NYSE: NVS), Akorn Inc. (NASDAQ: AKRX), Horizon Pharma Inc. (NASDAQ: HZNP) and Mallinckrodt PLC (NYSE: MNK). Free technical research on NVS, AKRX, HZNP and MNK can be downloaded upon signing up at:

S&P 500, Dow At New Highs; 14-Year High For Nasdaq
at Investor's Business Daily - Tue Jul 01, 4:07PM CDT
Stocks rallied Tuesday, lifting the key market averages to record or multiyear highs. The Nasdaq led with a 1.1% gain as Netflix (NFLX) surged 7%. The S&P 500 and Dow industrials added 0.7% and 0.8%, respectively, to all-time closing highs. Volume...

Stocks Rise In Strong Turnover; Netflix Soars On Upgrade
at Investor's Business Daily - Tue Jul 01, 12:22PM CDT
Buyers came into the market in spades Tuesday as growth stocks outperformed again. Several headlines fueled positive sentiment, including better than expected manufacturing data out of China and a Goldman Sachs upgrade of Netflix (NFLX). The Nasdaq...

Stocks Add To Gains; Salix, Akorn Ramp Higher
at Investor's Business Daily - Tue Jul 01, 10:52AM CDT
Stocks added to their gains and were close to session highs near Tuesday's halftime. The Nasdaq rallied 1.2% to a fresh 14-year high. Meanwhile, the S&P 500 rose 0.7% to a record high. The Dow Jones industrial average climbed 0.8%, with 28 of 30...

Akorn (AKRX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:13AM CDT
Akorn (AKRX) Shares March Higher, Can It Continue?

After Yesterday's Rally of 4.86% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Jun 30, 5:28PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $31.71 to a high of $33.31. Yesterday, the shares gained 4.9%, which took the trading range above the 3-day high of $31.89 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Stocks Mixed In Late Trade, But Growth Stocks Outperform
at Investor's Business Daily - Mon Jun 30, 1:58PM CDT
Stocks were narrowly mixed, but firming slightly going into the final hour of trading Monday, with volume running ahead of Friday's pace. In the stock market today, the Nasdaq rose 0.4%, the S&P 500 was up 0.1% and the Dow Jones industrial average...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Geothermal Energy Gets Boost with GRMS Adoption

Updated Category News Views 0

Geothermal's Big Leap with the GRMS The oil and gas sector didn't explode overnight—it leapt due to a consistent, standardized language that spoke to investors like a charm. Now, the geothermal industry is borrowing a page from this book of success with the Geothermal Resources Management System (GRMS). Finally, a framework not just built on hope and hot air, but...

Continue Reading
Hyliion Legal Woes Shake Investor Confidence

Updated Category News Views 0

Legal Storm Brews Over Hyliion Investments If you think riding the stock market is like sailing a calm sea, wake up. Hyliion Holdings Corp. (NYSE:HYLN) finds itself steaming headlong into rough waters. A securities class action lawsuit, Olmeta v. Hyliion Holdings Corp., accuses the company of embellishing its ambitions. The lawsuit cites potential wrongdoing in a...

Continue Reading
Mastering Power Efficiency with Phase Converters

Updated Category News Views 1

Powering Multiple Machines: A New Approach? You ever look at a workshop crammed with machines and wonder if it's all a waste of space, time, and money? Jay Yuergens from North America Phase Converter Co. gives us the lowdown on how one rotary or digital phase converter can handle the load. And let me tell you, it ain't as crazy as it sounds. It's all about finesse and...

Continue Reading
First Student Reduces Collisions by 63% with HALO Tech

Updated Category News Views 13

Making Every School Bus Ride Safer Here's some good news in the world of transportation, especially if you're keen on keeping kids safe on the daily school bus run. First Student's HALO™ Connected Transportation Platform claims it made a significant dent in reducing accidents—specifically, a 63% cut in forward collision risk. It's a big promise when you're talking...

Continue Reading
VIVIFY and ELISIUM Plan Hydrogen-Powered City

Updated Category News Views 1

Hydrogen Takes Center Stage in Urban Planning Well, I didn't see this one coming—a city that's planning the power before the buildings. We're talking about ELISIUM, the so-called cognitive city destined to rise in Hendry County, Florida. And leading the charge in all this energy planning? None other than VIVIFY Technology, set to bring in its hydrogen expertise right...

Continue Reading
New JPA Aims to Energize Inland Empire's Water Supply

Updated Category News Views 28

Fresh Steps in San Bernardino's Infrastructure Strategy Here's a twist for you: public agencies in San Bernardino County decided enough with the same old, same old and cooked up a new joint powers authority (JPA). They call it the San Bernardino Water and Power Authority, which sounds snappy enough for a meeting room nameplate, I reckon. Who's Steering the Ship? Leading...

Continue Reading
Plata Hits $1 Billion ARR in Record Digital Bank Growth

Updated Category News Views 14

Plata Rocks the Boat with Rapid Revenue Growth When a digital bank like Plata rakes in $1 billion in Annual Recurring Revenue (ARR) within just 3.5 years, you can't just shrug it off. That's blazing fast by any standard, especially for a financial institution. Emerging from Mexico, this bank's rocket-like ascent is flinging the doors wide open for what's possible in the...

Continue Reading
Honeywell Aerospace Faces Securities Fraud Lawsuit

Updated Category News Views 11

Turning Up the Heat on Honeywell Alright, strap in because things are getting tense over at Honeywell Aerospace (NASDAQ:HONA). Schall, Brown & Schwartz LLP (SBS) is stirring the pot with a class action lawsuit alleging some pretty deceptive business going-ons. From securities violations to misleading market statements, they aren’t holding back any punches. What’s This...

Continue Reading
Roof Inspections: Richmond's Key to Home Longevity

Updated Category News Views 17

Inspect, Protect, and Forget Your Worries Homeowners in the Greater Richmond area wisely take to heart the old saying: an ounce of prevention is worth a pound of cure. But let's cut through the noise for a moment and zero in on a foundational truth: regular roof inspections are not a luxury—they're an absolute must. Roofing expert Seth Brown, from BNH Roofing, makes it...

Continue Reading
Ryan Stills: Vegan Powerlifter Defies Odds, Wins Sixth World Title

Updated Category News Views 12

Ryan Stills: A Comeback Story for the Ages Ryan Stills isn't just lifting weights; he's lifting the entire perception of what's possible after a heavy surgical setback. We're talking about a guy who stared down a hemi-shoulder replacement—a career ender for many—and came out the other side with a whole new set of gold medals. Two years ago, some might have written him...

Continue Reading

Top 5 Most Recently Viewed Articles

Children’s Place Sees Stock Surge Post Impressive Q2 Results

Updated Category News Views 56

Children’s Place Stock Rises After Strong Q2 Earnings Children’s Place, Inc. (NASDAQ: PLCE) has recently attracted a lot of attention as its stock prices soared following the release of its second-quarter earnings. The positive results came as a welcome surprise just before the market opened, leading to a notable increase in trading volumes. Strong Earnings Exceed...

Continue Reading
Yunji Inc. Confirms Compliance with Nasdaq Standards

Updated Category News Views 61

Yunji Inc. (NASDAQ: YJ) made headlines recently after confirming it had regained compliance with Nasdaq standards, signaling a significant recovery from non-compliance issues that had threatened its standing on the exchange. Compliance Rollercoaster: From Non-Compliance to Recovery Backtracking a bit, Yunji faced a stark reality when it was flagged by Nasdaq under Listing...

Continue Reading
Ladybug Nutratech Drives Revenue Growth with Strategic Plans

Updated Category News Views 43

Ladybug Nutratech Unleashes Revenue Growth Initiatives Ladybug Resource Group, Inc. (OTC PINK: LBRG), now known as Ladybug Nutratech, is swiftly positioning itself as a frontrunner in the health and wellness sector. The company has demonstrated an impressive revenue growth of $6.0 million, which reflects an extraordinary increase of 10,527% compared to the same timeline...

Continue Reading
New Findings Show Duvakitug's Efficacy for Inflammatory Bowel Disease

Updated Category News Views 87

Groundbreaking Results from the Duvakitug Study Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA) and Sanofi SA (NASDAQ: SNY) have recently unveiled promising data from their RELIEVE UCCD Phase 2b study involving duvakitug, a new treatment for moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD), two prevalent types of inflammatory bowel disease (IBD)....

Continue Reading
Caliway's Innovative Weight Management Drug CBL-514 Advances Development

Updated Category News Views 126

Caliway's CBL-514 is Primed for Phase 2 Clinical Trial Caliway has recently completed its submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). This submission is critical as it paves the way for a Phase 2 clinical study focusing on weight management using CBL-514, an innovative drug candidate designed to address...

Continue Reading